If you’ve ever suffered through the burning discomfort of a urinary tract infection (UTI), you’ll know just how desperate you ...

In one study conducted by the NIH, it was found that dietary exposure to the drug caused tumors in two rodent species at two ...

NOW the sun is out, your SPF should be too. Did you know we are recommended to use two shot glasses worth of suncream to cover our body? It might seem excessive, but no patch should be left ...

The urinary recovery of nitrofurantoin after a single 100-mg oral dose was studied in subjects with varying renal function. Almost all uremic patients excreted little or no drug in the urine ...

In both studies, people were randomly assigned to take either Blujepa twice a day for five days or another antibiotic, nitrofurantoin (Macrobid), twice a day for five days. Nitrofurantoin is ...

Clinical research supports its efficacy. One study found that D-mannose reduced UTI recurrence as effectively as the antibiotic nitrofurantoin, with fewer side effects. Another showed that women ...

Currently, the most common treatment for uncomplicated UTIs in women is nitrofurantoin, an antibiotic that has been in use since the 1950s. Other options include trimethoprim-sulfamethoxazole and ...

Study participants were randomly assigned to receive gepotidacin 1500mg twice daily or nitrofurantoin 100mg twice daily for 5 days. The primary endpoint for both trials was the combined clinical ...

In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs. In the EAGLE-2 trial, Blujepa demonstrated non-inferiority, meaning it was at least as ...

As part of the research, scientists compared gepotidacin with nitrofurantoin, which is another common treatment for uUTIs (and bladder infections). The trials that evaluated gepotidacin involved ...

The FDA’s decision on Blujepa was supported by positive results from the late-stage EAGLE-2 and EAGLE-3 trials, which evaluated the drug against standard-of-care nitrofurantoin in female adults and ...